FDA approves first non-opioid treatment for opioid withdrawal — 3 insights

Written by Shayna Korol | May 17, 2018 | Print  |

The FDA approved the first non-opioid treatment for opioid withdrawal symptom management in adults.

Here are three things to know.

1. Lucemyra (lofexidine hydrochloride) may lessen the severity of opioid withdrawal symptoms; it is only approved for treatment for up to 14 days and may not completely prevent withdrawal symptoms.

2. Lucemyra is an oral, selective alpha 2-adrenergic receptor agonist that reduces the release of norepinephrine, which is believed to play a role in many opioid withdrawal symptoms.

3. An independent FDA advisory committee supported approving Lucemyra in March.

The treatment had fast-track designation and was reviewed under the FDA's priority review process.

More articles on practice management:

The CORE Institute plants roots in new medical campus: 3 takeaways

Orthopedic surgeon Dr. Armin Tehrany now a NYPD police surgeon: 5 things to know

Primary care compensation rose at rate nearly double of specialty: 6 things to note

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies here.

Top 40 Articles from the Past 6 Months